

HEALTH PARTNERS PLANS PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Antifibrotic Respiratory Agents

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:		Prescriber Name:		
HPP Member Number:		Fax:	Phone:	
Date of Birth:		Office Contact:		
Patient Primary Phone:		NPI:	PA PROMISe ID:	
Address:		Address:		
City, State ZIP:		City, State ZIP:		
Line of Business: Medicaid CHIP		Specialty Pharmacy (if applicable):		
Drug Name:		Strength:		
Quantity:		Refills:		
Directions:				
Diagnosis Code:	Diagnosis:			
HPP's maximum approval time is 12 months but may be less depending on the drug.				

Please attach any pertinent medical history including labs and information for this member that may support approval. <i>Please answer the following questions and sign.</i>			
	□ No		
Q2. Is the requested drug being prescribed for the treatment of a diagnosis that is indicated in the U.S. Food and Drug Administration (FDA)-approved package labeling OR a medically accepted indication?			
🗌 Yes	□ No		
Q3. Is the patient age-appropriate according to Food and Drug Administration (FDA)-approved package labeling, nationally recognized compendia or peer-reviewed medical literature?			
☐ Yes	□ No		
Q4. Is the prescribed dose consistent with Food and Drug Administration (FDA)-approved package labeling, nationally recognized compendia or peer-reviewed medical literature?			
☐ Yes	□ No		
Q5. Is the requested drug prescribed by or in rheumatologist, etc.)?	consultation with an appropriate specialist (e.g., pulmonologist,		
☐ Yes	□ No		
Q6. Have all potential drug interactions been addressed by the prescriber (such as discontinuation of the interacting drug, dose reduction of the interacting drug or counseling of the beneficiary of the risks associated with the use of both medications when they interact)?			
☐ Yes	□ No		
	ng to the sender that is legally privileged. This information is intended only for the use of the individual or prohibited from disclosing this information to any other party. If you are not the intended recipient, you are		

hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in

error, please notify the sender immediately to arrange for the return of this document

Page 1 of 3



HEALTH PARTNERS PLANS PRIOR AUTHORIZATION REQUEST FORM

Antifibrotic Respiratory Agents

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:		
Q7. Does the patient have a history of a contraindication to the prescribed medication?			
☐ Yes	□ No		
Q8. Does the patient currently smoke?			
☐ Yes	□ No		
Q9. Is there documentation of being advised by the prescriber to stop smoking?			
☐ Yes	□ No		
Q10. Is the requested drug a non-preferred idiopathic pulmonary fibrosis (IPF) agent?			
☐ Yes	□ No		
Q11. Does the patient have history of therapeutic failure, contraindication or intolerance to the preferred idiopathic pulmonary fibrosis (IPF) agents approved or medically accepted for the patient's indication?			
☐ Yes	□ No		
Q12. Does the patient have a current history (within the past 90 days) of being prescribed the same non-preferred idiopathic pulmonary fibrosis (IPF) agent?			
☐ Yes	□ No		
Q13. Is the patient benefitting from the requested drug, based on the prescriber's assessment?			
☐ Yes	□ No		
Q14. Have all potential drug interactions been addressed by the prescriber (such as discontinuation of the interacting drug, dose reduction of the interacting drug or counseling of the beneficiary of the risks associated with the use of both medications when they interact)?			
☐ Yes	□ No		
Q15. Is the requested drug prescribed by or in consultation with an appropriate specialist (e.g., pulmonologist, rheumatologist, etc.)?			
☐ Yes	□ No		
Q16. Does the patient have a history of a contraindication to the prescribed drug?			
☐ Yes	□ No		
Q17. Additional Information:			

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



HEALTH PARTNERS PLANS PRIOR AUTHORIZATION REQUEST FORM

Antifibrotic Respiratory Agents

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name: Prescriber Name:

Prescriber Signature

Date

Updated for 2023

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document